Intravesical treatment of non-muscle-invasive bladder cancer

被引：0
作者：
Bahlburg, Henning [1 ]
Noldus, Joachim [1 ]
Roghmann, Florian [1 ]
机构：
[1] Univ Klinikum Ruhr Univ Bochum, Marien Hosp Herne, Klin Urol & Neurourol, Holkeskampring 40, D-44625 Herne, Germany
来源：
UROLOGIE | 2025年 / 64卷 / 03期
关键词：
Bacillus Calmette-Gu & eacute; rin; Bladder carcinoma; Intravesical treatment; Bladder-preserving strategy; Mitomycin C; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; MITOMYCIN-C; FORMAL METAANALYSIS; BCG IMMUNOTHERAPY; CHEMOTHERAPY; RECURRENCE; RISK; INSTILLATION; EXPRESSION;
D O I：
10.1007/s00120-025-02522-8
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Depending on the risk status, the treatment options for non-muscle-invasive bladder cancer (NMIBC) can include a bladder-preserving strategy with intravesical instillation treatment or early radical cystectomy. Established intravesical treatment options such as mitomycin C (MMC) or Bacillus Calmette-Gu & eacute;rin (BCG) are available to reduce the probability of progression and recurrence. This article classifies the intravesical treatment options in the therapeutic landscape of NMIBC and provides an overview of the indications and application regimens.
引用
收藏
页码：288 / 294
页数：7
相关论文
共 29 条
[1]   Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial [J].
Angulo, Javier C. ;
Alvarez-Ossorio, Jose L. ;
Dominguez-Escrig, Jose L. ;
Moyano, Jose L. ;
Sousa, Alejandro ;
Fernandez, Jesus M. ;
Gomez-Veiga, Francisco ;
Unda, Miguel ;
Carballido, Joaquin ;
Carrero, Victor ;
Fernandez-Aparicio, Tomas ;
de Jalon, Angel Garcia ;
Solsona, Eduardo ;
Inman, Brant ;
Palou, Joan .
EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (01) :58-66
[2]   Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial [J].
Au, JLS ;
Badalament, RA ;
Wientjes, MG ;
Young, DC ;
Warner, JA ;
Venema, PL ;
Pollifrone, DL ;
Harbrecht, JD ;
Chin, JL ;
Lerner, SP ;
Miles, BJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (08) :597-604
[3]   European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) [J].
Babjuk, Marko ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Escrig, Jose L. Dominguez ;
Gontero, Paolo ;
Liedberg, Fredrik ;
Masson-Lecomte, Alexandra ;
Mostafid, A. Hugh ;
Palou, Joan ;
van Rhijn, Bas W. G. ;
Roupret, Morgan ;
Shariat, Shahrokh F. ;
Seisen, Thomas ;
Soukup, Viktor ;
Sylvester, Richard J. .
EUROPEAN UROLOGY, 2022, 81 (01) :75-94
[4]   Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [J].
Balar, Arjun, V ;
Kamat, Ashish M. ;
Kulkarni, Girish S. ;
Uchio, Edward M. ;
Boormans, Joost L. ;
Roumiguie, Mathieu ;
Krieger, Laurence E. M. ;
Singer, Eric A. ;
Bajorin, Dean F. ;
Grivas, Petros ;
Seo, Ho Kyung ;
Nishiyama, Hiroyuki ;
Konety, Badrinath R. ;
Li, Haojie ;
Nam, Kijoeng ;
Kapadia, Ekta ;
Frenkl, Tara ;
de Wit, Ronald .
LANCET ONCOLOGY, 2021, 22 (07) :919-930
[5]   Role of urothelial cells in BCG immunotherapy for superficial bladder cancer [J].
Bevers, RFM ;
Kurth, KH ;
Schamhart, DHJ .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :607-612
[6]  
Böhle A, 2004, UROLOGY, V63, P682, DOI 10.1016/j.urology.2003.11.049
[7]   Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].
Böhle, A ;
Jocham, D ;
Bock, PR .
JOURNAL OF UROLOGY, 2003, 169 (01) :90-95
[8]   Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer [J].
Böhle, A ;
Brandau, S .
JOURNAL OF UROLOGY, 2003, 170 (03) :964-969
[9]   Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC) - avoidance, recognition, management and consent [J].
Elmamoun, Mamoun H. ;
Christmas, Tim J. ;
Woodhouse, Christopher R. J. .
BJU INTERNATIONAL, 2014, 113 (5B) :E34-E38
[10]  
Food and Drug Administration, 2018, US
123